DOMA Challenges Pacira Board with Fresh Nominees

DOMA Perpetual Capital Management is pushing to shake things up at Pacira BioSciences. They own about 7.5% of Pacira's stock and have put forward three new nominees for the board, arguing that fresh perspectives are needed to improve the company's performance and governance. The current board has dismissed these nominees as unqualified, but DOMA insists their nominees have the expertise that fits Pacira's challenges, like the opioid crisis and patent issues. What does it mean for you? If you're a shareholder, your vote could influence how Pacira is run. This might impact the company's future strategy and, consequently, your investment returns. Keep an eye on developments if you have a stake in Pacira.